Clinical trials will be rigged.
https://nyulangone.org/news/clinical-trial-tests-efficacy-common-antimalarial-drug-prevent-covid-19-infection
NYU Langone Health researchers are co-leading a major clinical trial to determine whether the common antimalarial medication hydroxychloroquine can help prevent 2019 coronavirus disease (COVID-19) infections. The drug, marketed as Plaquenil®, has attracted considerable media attention, but definitive evidence is lacking on whether it can thwart infections in people who have been exposed to the novel coronavirus known as SARS-CoV-2
The post-exposure prophylaxis (PEP) trial was inspired by similar efforts to prevent infections in people exposed to HIV. The $9.5 million study is being funded by the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation in partnership with the Wellcome Trust and Mastercard to speed the identification and testing of potential treatments.